ArticleESMO open2026
Automating tumor-stroma ratio quantification in colon cancer patients from the UNITED study.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumour-Stroma Ratio as a Predictive Biomarker for Neoadjuvant Therapy Efficacy in Rectal Cancer.Cancers · 2026Review
- Prognostic Role of Worst Pattern of Invasion in Oral Squamous Cell Carcinoma.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColon cancer is a leading cause of cancer-related death worldwide, making accurate prognostic tools crucial. The tumor-stroma ratio (TSR) quantifies the proportion of stromal to tumor epithelial tissue and is a prognosticator in colon cancer. Stroma-high tumors are associated with worse outcomes and less benefit from adjuvant chemotherapy (ACT). Transitioning from visual to automated TSR scoring coincides with digital pathology advancements. MATERIALS AND
methodsIn this study, we validated a fully automated artificial intelligence-based TSR quantification algorithm in hematoxylin-eosin-stained slides from the UNITED cohort, including 853 stage II and III colon cancer patients who had not received neoadjuvant therapy. The algorithm segmented 11 tissue classes on whole-slide images and calculated TSR as stroma/(stroma + epithelial tumor). A 1-mm region of interest was implemented, and an optimal automated cut-off of 77% was derived using receiver operating characteristic analyses for disease-free survival (DFS) and overall survival (OS).
resultsThe median patient age was 67 years. Stroma-high patients had significantly worse DFS than stroma-low patients (3-year DFS 71% versus 82%, P < 0.001). This prognostic effect remained significant in the multivariate analysis (P = 0.016) and was consistent across stage II and III subgroups. Importantly, worse DFS was observed in both stroma-high stage II and III patients despite ACT (3-year DFS 74% versus 89%, P = 0.015; and 65% versus 79%, P = 0.002, respectively), suggesting potential predictive value. OS was worse in stroma-high patients as well (5-year OS 69% versus 85%, P = 0.002).
conclusionWe validated a clinically applicable tool for fully automated TSR quantification in colon cancer, including an optimal region of interest and cut-off value for automated scoring. We confirm the independent prognostic value of automated TSR for DFS and OS and highlight its influence on potential ACT benefit, underlining its clinical relevance. Our findings support its integration into digital pathology workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.